Abstract
Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia (CRA). This may be related in part to the dysregulation of iron metabolism, leading to functional iron deficiency. However, the use of iron supplementation during treatment with ESA has not been pursued as rigorously in anemic patients with cancer as it has in patients with chronic kidney disease. In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue.
| Original language | English |
|---|---|
| Pages (from-to) | 1169-1173 |
| Number of pages | 5 |
| Journal | Cancer |
| Volume | 115 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Mar 15 2009 |
Fingerprint
Keywords
- Cancer anemia
- Chemotherapy
- Erythropoiesis-stimulatory agents
- Iron supplementation
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. / Pedrazzoli, Paolo; Rosti, Giovanni; Secondino, Simona; Siena, Salvatore.
In: Cancer, Vol. 115, No. 6, 15.03.2009, p. 1169-1173.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia
AU - Pedrazzoli, Paolo
AU - Rosti, Giovanni
AU - Secondino, Simona
AU - Siena, Salvatore
PY - 2009/3/15
Y1 - 2009/3/15
N2 - Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia (CRA). This may be related in part to the dysregulation of iron metabolism, leading to functional iron deficiency. However, the use of iron supplementation during treatment with ESA has not been pursued as rigorously in anemic patients with cancer as it has in patients with chronic kidney disease. In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue.
AB - Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia (CRA). This may be related in part to the dysregulation of iron metabolism, leading to functional iron deficiency. However, the use of iron supplementation during treatment with ESA has not been pursued as rigorously in anemic patients with cancer as it has in patients with chronic kidney disease. In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue.
KW - Cancer anemia
KW - Chemotherapy
KW - Erythropoiesis-stimulatory agents
KW - Iron supplementation
UR - http://www.scopus.com/inward/record.url?scp=63449089728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63449089728&partnerID=8YFLogxK
U2 - 10.1002/cncr.24115
DO - 10.1002/cncr.24115
M3 - Article
VL - 115
SP - 1169
EP - 1173
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 6
ER -